根据最新提交至美国证券交易委员会(SEC)的文件披露,生物技术公司TransCode Therapeutics(股票代码:RNAZ)旗下针对癌症治疗的创新疗法TTX-MC138,计划于2026年上半年进入二期a阶段临床试验。这一进展标志着该疗法在临床开发路径上迈出关键一步,为后续研究奠定基础。
根据最新提交至美国证券交易委员会(SEC)的文件披露,生物技术公司TransCode Therapeutics(股票代码:RNAZ)旗下针对癌症治疗的创新疗法TTX-MC138,计划于2026年上半年进入二期a阶段临床试验。这一进展标志着该疗法在临床开发路径上迈出关键一步,为后续研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.